The acute myeloid leukemia is the cancer most common blood in adults, with approximately 120,000 cases per year. Disease hits the blood cell factory (the bone marrow) and causes the galloping production of defective cells. The three-year survival rate barely reached 25%. But there is hope.
The pill, called Revumeniballowed the complete disappearance of the signs of cancer in almost one in three participants in the US clinical trial. The results are preliminary and do not imply a definitive cure, but the scientists behind the experiment are optimists.
Very encouraging results
Revumenib obtained very encouraging results in its phase I, according to the scientific journal Nature. The clinical trial revealed that out of 60 patients, 53% responded to the drug and 30% got a full response.
The researchers focused on two genetic subtypes in which a protein, called menina, facilitates the progression of leukemia. Revumenib binds to this protein and inhibits it, thanks to its complex chemical recipe. A formula that has so far saved the lives of 18 people.
